$TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Dipal Doshi
CEO
183
Employees
$11.31
Current Price
$421.18M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 4 | $410,149.50 | 31,487 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $508,041.64 | 39,475 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $508,041.64 | 39,475 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $508,041.64 | 39,475 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Dowden Nathan J President & COO | Sale | 3,116 | $13.02 | $40,582.78 | View Details |
| Mar 10, 2026 | Dowden Nathan J President & COO | Sale | 11,894 | $13.05 | $155,188.15 | View Details |
| Mar 9, 2026 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | 5,089 | $13.00 | $66,162.60 | View Details |
| Mar 10, 2026 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | 11,388 | $13.02 | $148,215.96 | View Details |
| Mar 4, 2026 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | 7,988 | $12.25 | $97,892.14 | View Details |
35 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$1.32
ActualN/A
Revenue
Estimated$7.41M
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$MDGL โ MADRIGAL PHARMACEUTICALS, INC.via BAKER BROS. ADVISORS LP$KOD โ Kodiak Sciences Inc.via BAKER BROS. ADVISORS LP$CELC โ Celcuity Inc.via BAKER BROS. ADVISORS LP$IMCR โ Immunocore Holdings plcvia BAKER BROS. ADVISORS LP$DNLI โ Denali Therapeutics Inc.via BAKER BROS. ADVISORS LP$KYMR โ Kymera Therapeutics, Inc.via BAKER BROS. ADVISORS LP